CompletedPhase 2

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

United States304 participantsStarted 2009-10

Plain-language summary

RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with refractory solid tumors.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. ongoing or active infection
✕. diabetes mellitus
✕. hypertension
✕. symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months

What they're measuring

Response Rates

Timeframe: 10 years

Trial details

NCT IDNCT01037790

SponsorAbramson Cancer Center at Penn Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-10

Results submitted2021-02-18

View on ClinicalTrials.gov More Adult Solid Tumor trials